Meng Y N, Shi Q, Cheng S, Wang L, Zhao W L
State Key Laboratory of Medical Genomics; Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Department of Hematology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Xuzhou Center Hospital, Xuzhou 221009, China.
State Key Laboratory of Medical Genomics; Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Department of Hematology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Zhonghua Xue Ye Xue Za Zhi. 2019 Aug 14;40(8):639-643. doi: 10.3760/cma.j.issn.0253-2727.2019.08.003.
To observe whether the history of solid tumors affects the treatment response and survival situation of patients with diffuse large B-cell lymphoma (DLBCL) . A retrospective study was conducted in 836 patients with DLBCL who were treated in the Department of Hematology at Ruijin Hospital from 2013 to 2018. Among them, 34 DLBCL patients who had the history of solid tumors were classified into double cancer group. From 802 patients without history of solid tumors, 68 DLBCL patients were selected as control group, using 1∶2 matching on propensity scores for age, gender, IPI score and etc. All patients included in the study had follow-up interviews through medical record and telephone for mortality from any cause. Treatment response and 3-year overall survival (OS) and progression-free survival (PFS) of two groups were analyzed. The complete remission rates after RCHOP (Rituximab+Cyclophosphamide+Vincristine+Adriamycin 50 mg/m(2) or Epirubicin or Liposome Adriamycin+Prednisone) regimen were 79.4% and 67.6% in the double cancer group and the control group, respectively (=0.210) . Among the 102 patients, 6 patients died in the double cancer group while 24 patients died in the control group and the median survival time of both two groups were not reached. The 3-year OS were (74.7±9.5) % and (63.5±6.1) % ((2)=2.791, =0.095) , while 3-year PFS were (72.1±8.8) % and (54.3±6.4) % ((2)=1.400, =0.237) in the double cancer group and the control group, respectively. The history of solid tumors didn't affect DLBCL patients' treatment response and short-term survival.
观察实体瘤病史是否影响弥漫性大B细胞淋巴瘤（DLBCL）患者的治疗反应及生存情况。对2013年至2018年在瑞金医院血液科接受治疗的836例DLBCL患者进行回顾性研究。其中，34例有实体瘤病史的DLBCL患者被归入双癌组。从802例无实体瘤病史的患者中，选取68例DLBCL患者作为对照组，按照年龄、性别、国际预后指数（IPI）评分等倾向得分进行1∶2匹配。纳入研究的所有患者均通过病历和电话进行随访，了解任何原因导致的死亡情况。分析两组的治疗反应以及3年总生存（OS）率和无进展生存（PFS）率。双癌组和对照组接受利妥昔单抗+环磷酰胺+长春新碱+阿霉素50mg/m²或表柔比星或脂质体阿霉素+泼尼松（RCHOP）方案后的完全缓解率分别为79.4%和67.6%（P=0.210）。在这102例患者中，双癌组有6例死亡，对照组有24例死亡，两组的中位生存时间均未达到。双癌组和对照组的3年OS率分别为（74.7±9.5）%和（63.5±6.1）%（χ²=2.791，P=0.095），而3年PFS率分别为（72.1±8.8）%和（54.3±6.4）%（χ²=1.400，P=0.237）。实体瘤病史不影响DLBCL患者的治疗反应及短期生存。
